Home » Topics » BioWorld Science

BioWorld Science
RSS

U.S. researchers patent ATR kinase inhibitors

Oct. 9, 2019

Faron receives DMC feedback for phase I/II MATINS trial of Clevegen

Oct. 9, 2019

GSK and Lyell Immunopharma collaborate to improve cell therapies for cancer

Oct. 9, 2019

Scenesse wins approval in U.S. for erythropoietic protoporphyria

Oct. 9, 2019

Tezepelumab reduces activation of matrix remodeling and inflammatory pathways

Oct. 9, 2019

FDA approves Wilate for hemophilia A

Oct. 9, 2019

MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma

Oct. 9, 2019

MinL4.0 RSV: a synthetic, live-attenuated vaccine against respiratory syncytial virus

Oct. 9, 2019

Preliminary data presented from phase I/II ASPIRO study of AT-132

Oct. 9, 2019

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Oct. 9, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...